MINERALYS THERAPEUTICS INC (MLYS)
NASDAQ • Healthcare
Last close at August 10, 2026 at 20:00 UTC
Fundamentals Charts
About MINERALYS THERAPEUTICS INC
Mineralys Therapeutics, Inc. is a NASDAQ-listed healthcare company in biotechnology that develops medicines for diseases driven by abnormally elevated aldosterone. In qualitative terms, it is a clinical-stage drug developer rather than a commercial biopharma business, with its work centered on cardiorenal disorders tied to excess aldosterone.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
MINERALYS THERAPEUTICS INC's Technical Indicators Summary
MLYS exhibits modest bullishness anchored by price trading above its short- and medium-term averages while longer-term averages remain higher, signaling mixed timeframe dynamics. Momentum readings are tepid overall — RSI around midrange and MACD near neutral — yet a positive CCI and steady on-balance volume suggest selective buying interest. ADX is low, indicating the trend lacks conviction, and volatility is moderate per ATR. The price sits essentially at the classic pivot, reflecting a neutral immediate bias. Technical takeaway: short-term moving averages and volume favor buyers, but weak trend strength and higher long-term averages temper conviction.
| Indicator | Value |
|---|---|
RSI (14) | 54.24 |
Stochastic %K (14, 3, 3) | 70.68 |
CCI (20) | 104.75 |
WPR (14) | -25.00 |
Momentum (10) | 0.17 |
MFI | 48.78 |
MACD Level (12, 26) | -0.05 |
Bollinger Bands | $25.77 - $27.91 |
ATR (14) | $1.19 (4.34%) |
ADX (14) | 10.41 |
OBV | 14,971,105 |
Classic Pivot Point | $27.31 |
Fibonacci Pivot Point | $27.31 |
Simple Moving Averages | $26.59 - $31.03(5 indicators) |
Exponential Moving Averages | $26.87 - $30.07(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
The last session saw a slight bid for MLYS, which crept 0.11% higher by the close. MLYS faces potential near-term selling pressure after David Rodman files Rule 144 for a stock sale.
Trading Volume
Above 10d avg 616.3K
817.1K
vs S&P 500 Today
Moderate Outperformance
+0.17%
52-Week Position
Mid-range
42.2%
Updated: August 11, 2026 at 12:10 UTC